Leveraging human genetics to develop future therapeutic strategies in rheumatoid arthritis.
The purpose of this article is to place these genetic discoveries in the context of current and future therapeutic strategies for patients with RA. More specifically, this article focuses on (1) a brief overview of genetic studies, (2) human genetics as an approach to identify the Achilles heel of disease pathways, (3) humans as the model organism for functional studies of human mutations, (4) pharmacogenetic studies to gain insight into the mechanism of action of drugs, and (5) next-generation patient registries to enable large-scale genotype-phenotype studies.
Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, Suite 168, Boston, MA 02115, USA. rplenge@partners.org <rplenge@partners.org>
Robert M
RM
Plenge
Soumya
S
Raychaudhuri
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics*; D055808:Drug Discovery / Q000379:methods*; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D010641:Phenotype; D012042:Registries; D012307:Risk Factors
D018501:Antirheumatic Agents